Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.
Animals
Antineoplastic Agents
/ chemistry
Area Under Curve
Cell Cycle Proteins
/ antagonists & inhibitors
Cell Line, Tumor
Dogs
Drug Design
Drug Discovery
Gene Expression Regulation, Neoplastic
/ drug effects
Half-Life
Humans
Male
Mice
Mice, Nude
Models, Molecular
Molecular Structure
Protein Conformation
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Rats
Rats, Sprague-Dawley
Xenograft Model Antitumor Assays
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
09 09 2021
09 09 2021
Historique:
pubmed:
24
8
2021
medline:
15
12
2021
entrez:
23
8
2021
Statut:
ppublish
Résumé
Wee1 inhibition has received great attention in the past decade as a promising therapy for cancer treatment. Therefore, a potent and selective Wee1 inhibitor is highly desirable. Our efforts to make safer and more efficacious Wee1 inhibitors led to the discovery of compound
Identifiants
pubmed: 34423975
doi: 10.1021/acs.jmedchem.1c01121
doi:
Substances chimiques
Antineoplastic Agents
0
Cell Cycle Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
WEE1 protein, human
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM